Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dana Farinella
OpenAlex ID:
A5115006254
Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study
2024
·
John M. Burke
, Ian W. Flinn
, et al.
·
Blood
·
3
PDF
Show more works
View as search
Works count:
1
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type
